Clinical Trial Detail

NCT ID NCT02798536
Title Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

malignant epithelial mesothelioma

malignant biphasic mesothelioma

Therapies

LMB-100

LMB-100 + Nab-paclitaxel

Age Groups: adult senior

No variant requirements are available.